MRNA · Q1 2026 Earnings

Narrative arc: Q2 FY25 — COVID franchise erosion, headcount cut → Q3 FY25 — opex cuts deepen, CMV fails, pipeline pruning → Q1 FY26 — return-to-growth narrative paired with pipeline catalyst calendar and litigation overhang quantified.

The growth narrative has flipped from defense to offense, but the FY ceiling tells the real story. Two quarters ago management was defending a shrinking COVID franchise and cutting FY guidance high-end. This quarter the press release opens with "we are excited to return to sales growth in 2026" and the prepared materials emphasize the Q1 beat and 309% net product sales growth. From the call: "Building on this strong first quarter momentum, we are excited to return to sales growth in 2026." But the FY guide is capped at 10% growth and Q2 is guided to $50–$100M. The tonal shift toward growth language is not matched by the numerical commitment — management is letting the Q1 print do narrative work that the FY ceiling does not support.

Pipeline framing has shifted toward portfolio breadth over binary catalysts. This quarter management emphasized the catalyst calendar — Intismeran melanoma Phase 3 interim, norovirus Phase 3, propionic acidemia registrational, flu PDUFA August 5 — as an embarrassment of riches rather than make-or-break. The Intismeran framing in particular has shifted: management is now describing it as potential monotherapy in earliest-stage disease (Stage 1 non-small cell lung cancer Phase 3 initiated) with the hazard-ratio success zone defined as anywhere from 0.5 to 0.8 — a deliberately wide success zone that signals commercial preparation rather than scientific uncertainty.

The litigation overhang is now sized but not settled. The $878M Section 1498 settlement is in the P&L and the cash guidance, with management disclosing potential additional exposure of $1.3B if the Federal Circuit affirms — but characterizing it as "not probable" and timeline-deferred to late 2027 or 2028. The risk is quantified and pushed out, but not removed.

Cost discipline language has narrowed from a productivity story to an explicit cash-runway story. Q1 FY26 R&D down 24% YoY, SG&A down 18%, and the new FY2026 framework gives total cash costs of $4.2B (excluding litigation) — close to the 2027 $4.2B cash cost target that management has cited as the path to 2028 breakeven. The cost-out is delivering. The question is whether revenue grows fast enough to meet a flat cost base.